EmendoBio, Inc.
New York
About EmendoBio, Inc.
Emendo was set up to expand what is possible in genome editing. They believe that challenges can be overcome by fusing expertise in diverse disciplines, and by looking at the core questions with a new approach. Having studied at top academic institutions, including the Weizmann Institute, Emendo’s founders came together to pool their collective knowledge of protein engineering and DNA repair to achieve a shared goal: the creation of genetic medicines that deliver on the promise of gene editing. By transforming the available tools, they are able to address those disorders and diseases that are currently considered to be untreatable. Working at the cutting edge of gene editing, the Emendo team combines knowledge, expertise and proven scientific methodologies, with creativity, ingenuity and daring to push the boundaries and achieve more.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $317.8M
- Funding stage: M&A
- Last round: Corporate Round (Dec 2020)
- Website: emendobio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/emendobio-inc-42662 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.